GlassScriptPhysician profile
Suman M Reddy
NPI 1447363247
$7,644.98
in general payments reported to CMS, 2019-2025
32 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $689 · 2021: $1,863 · 2022: $699 · 2023: $1,334 · 2024: $792 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,427 · Education: $21.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,427.22 |
| Education | $21.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,382.76 | 2019-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $1,052.20 | 2022-2025 | Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $866.30 | 2019-2022 | |
| Amgen INC. | $836.34 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Vifor Pharma, INC. | $749.29 | 2019-2025 | Veltassa, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $653.61 | 2020-2024 | Jardiance |
| Akebia Therapeutics INC | $358.74 | 2019-2025 | Vafseo, Auryxia |
| Aurinia Pharma U.S., INC. | $192.55 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $188.04 | 2021-2025 | |
| Travere Therapeutics, INC. | $160.26 | 2023-2025 | |
| Lilly USA, LLC | $157.98 | 2021-2025 | Jardiance, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $131.05 | 2021 | |
| Horizon Therapeutics Plc | $129.18 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $85.63 | 2019-2022 | |
| Exact Sciences Corporation | $83.11 | 2024-2025 | Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $59.53 | 2025 | Tarpeyo |
| Pfizer INC. | $59.14 | 2019 | |
| Ardelyx, INC. | $55.36 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $51.46 | 2019-2021 | |
| Medtronic, INC. | $48.06 | 2021 | |
| Glaxosmithkline, LLC. | $45.95 | 2019-2021 | |
| Shield Therapeutics INC | $45.51 | 2023 | Accrufer |
| Fresenius USA Marketing, INC. | $42.04 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $38.64 | 2023-2024 | Givlaari |
| Scpharmaceuticals INC. | $29.07 | 2025 | |
| Kyowa Kirin, INC. | $27.47 | 2023 | Crysvita |
| Novartis Pharmaceuticals Corporation | $25.59 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.21 | 2023 | Jynarque |
| Opko Pharmaceuticals, LLC | $21.03 | 2023 | Rayaldee |
| Arbor Pharmaceuticals, INC. | $15.79 | 2019 | |
| Renalytix Ai, INC. | $15.68 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Dexcom, INC. | $13.41 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suman Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.